March 6, 2014
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Notice Concerning the Issuance of Stock Acquisition Rights asStock Option to Directors

SymBio Pharmaceuticals Limited (“the Company”) announces that at a Board of Directors’ meeting(“the Board”) held today, it has decided to submit, for discussion at the 9th Ordinary General
Meeting of Shareholders that will be held on March 27, 2014 (“the Shareholders’ Meeting”), a
proposal as to the amount of compensation and its content in connection with stock acquisition rights
to be issued to the Company’s Directors.
1. Reason for proposal
The Board will propose to issue stock acquisition rights as stock options to the Company’s
Directors aiming to enhance their motivations and morale towards improved performance.
Where the amount of compensation has been approved by the 8th Ordinary General Meetingof Shareholders held on March 28, 2013, pursuant to Article 361 of the Companies Act, theBoard will propose to modify the contents of stock acquisition rights and allot the stockacquisition rights as stock compensation-type stock options to Directors, as described below.
Regardless of modifying the contents of stock acquisition rights based on the approval ofthis proposal, the stock acquisition rights as stock options shall be granted to the Company’s
Directors as the compensation pursuant to Article 361, Section 1 within the annual amount of
80,000,000 yen (of which, 22,000,000 yen to Outside Directors), as already approved by the 8th
Ordinary General Meeting of Shareholders.
The amount of compensation shall be calculated by multiplying the fair value of one stockacquisition right calculated based on various conditions including market price of stock andexercise price on the allotment date by the total number of stock acquisition rights allotted toDirectors of the Company. Although it has been approved by the Extraordinary General
Meeting of Shareholders held on August 3, 2005 that the aggregate amount of compensation for
the Company’s Directors shall be 130,000,000 yen or less per year, the Board will ask for theapproval of this proposal separately from the aforementioned amount of the compensation to
the Company’s Directors. Upon allotment of the proposed stock acquisition rights, theCompany shall pay monetary compensation which is equivalent to the amount to be paid for thestock acquisition rights to the Directors to whom such stock acquisition rights are allotted, andthe Directors shall set off their claim for such compensation in lieu of the payment for the stockacquisition rights.
2. Subscription Guidelines(1) Persons to whom stock acquisition rights will be allotted
The stock acquisition rights shall be allotted to the Company’s Directors.
If another proposal concerning the election of Directors is resolved at the Shareholders’Meeting, the number of the Company’s Directors would be six (6) (of which, five (5) are
Outside Directors). However, only five (5) existing Directors (of which, four (4) are OutsideDirectors) would be subject to allotment of the proposed stock acquisition rights.

(2) Contents of stock acquisition rights as stock compensation-type stock options to Directors
The contents of stock acquisition rights to be granted to Directors as stock options shall be as
follows:(a) Class and number of shares to be issued upon exercise of stock acquisition rights
The number of shares to be issued upon exercise of one unit of stock acquisition right(hereinafter the “Number of Granted Shares”) shall be 100 shares of the Company’scommon stock. However, in the event that adjustments are made to the number of sharesas set forth below, adjustments shall be made likewise.
In the event that the Company makes a stock split or stock consolidation, the number ofshares subject to unexercised stock acquisition rights shall be adjusted using the formulaset forth below, and any fractions less than one share resulting therefrom shall be rounded
down.
(Number of shares after adjustment) = (Number of shares before adjustment) x (Ratio ofsplit or consolidation)
In addition to aforementioned cases, in the event it is necessary to adjust the number ofshares to which stock acquisition rights have not been exercised, the Company may makereasonable adjustments.
(b) Total number of stock acquisition rights
Total number of stock acquisition rights issued within one year from the date of theOrdinary General Meeting of Shareholders for each business year shall not exceed thenumber obtained by dividing aforementioned annual amount of 80,000,000 yen by the fairvalue of one stock acquisition right calculated based on various conditions including
market price of stock and exercise price on the allotment date. (Any fraction of less than
one shall be rounded down.)(c) Amount to be paid for stock acquisition rightsThe amount to be paid shall be the fair value of stock acquisition rights on the allotment
day of stock acquisition rights as calculated using the Black-Scholes Model. The person
who receives the allotment of stock acquisition rights shall set off his/her claims forcompensation against the Company in lieu of payment of monies for the stock acquisitionrights allotted.
(d) Value of property to be contributed upon exercise of stock acquisition rights and its
calculation method
The value of property to be contributed upon exercise of stock acquisition rights shall be
determined by multiplying the exercise price per share to be issued, set as one (1) yen, andmultiply by the number of shares allotted.
(e) Period for exercising stock acquisition rights
The period for exercising stock acquisition rights shall be determined at the meeting ofBoard of Directors, sometime between the next day of allotment of stock acquisition rights
and the day on which ten (10) years have passed after such allotment.
(f) Conditions for exercising stock acquisition rights(i) The holder of the stock acquisition rights (the “Allottee”) must be the Company’s
Director at the time of exercise. However, if the person retires due to expiry of her/histerm or other such legitimate reason, such requirement may be waived.
(ii) Each Stock Option may not be partially exercised.
(iii) If an organizational restructuring is approved by the resolution of the Company’s
Shareholders’ meeting (including the case where resolution of a Shareholders’meeting is deemed to exist pursuant to the provision of Article 319 of the Companies

Act) or the Board of Directors’ meeting (limited to the case where no Shareholders’meeting is required for the relevant organizational restructuring) before the exercise
period (hereinafter the “Exercise Period”) of the stock acquisition rights starts, theAllottee may exercise the rights starting from the date of resolution by theShareholders’ meeting or the Board of Directors’ meeting until one day before theeffective date of the organizational restructuring. The organizational restructurings
subject to this condition are: an absorption-type merger or an incorporation-typemerger where the Company becomes a dissolving company, an absorption-type split
or an incorporation-type company split where the Company becomes a split company
or a share exchange or a share transfer where the Company becomes a wholly-owned
subsidiary.
(iv) In the event where the Allottee dies, in accordance with the contract for allotment ofstock acquisition rights between the Company and the Allottee, the inheritor assumes
the rights of the Allottee and may exercise such rights.
(v) Other conditions relating to exercise shall be determined resolution in the Board ofDirectors’ meetings.
(g) Limitations on obtaining the proposed stock acquisition rights by transfer
The approval from the Company’s Board of Directors shall be required to obtain proposed
stock acquisition rights by transfer.
(h) Other matters regarding stock acquisition rights
The Bylaws set out in (a) to (g) above and other matters relating to stock acquisition rights
shall be determined by resolution by the Company’s Board of Directors’ meeting where
decisions regarding offering of stock acquisition rights are to be discussed.

(Note) The issuance of the above mentioned stock acquisition rights is subject to the resolution by
the 9th Ordinary General Meeting of Shareholders that will be held on March 27.

[Contact]
Investor Relations
Tel: +81(0)3 5472 1125